- Home
- SPRY vs GFUZ Comparison
SPRY vs GFUZ Comparison
Compare SPRY & GFUZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SPRY | GFUZ |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electric Utilities: Central |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 788.5M | 687.0M |
| IPO Year | 2020 | 2025 |
Fundamental Metrics
Financial Performance| Metric | SPRY | GFUZ |
|---|---|---|
| Price | $5.64 | $6.43 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $40.00 | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 337.3K |
| Earning Date | 05-11-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $84,278,000.00 | N/A |
| Revenue This Year | $87.40 | N/A |
| Revenue Next Year | $81.64 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.76 | $6.51 |
| 52 Week High | $18.50 | $9.98 |
Technical Indicators
Market Signals| Indicator | SPRY | GFUZ |
|---|---|---|
| Relative Strength Index (RSI) | 23.59 | 27.63 |
| Support Level | N/A | N/A |
| Resistance Level | $8.61 | $9.98 |
| Average True Range (ATR) | 0.44 | 1.12 |
| MACD | -0.18 | -0.21 |
| Stochastic Oscillator | 2.54 | 7.97 |
Price Performance
Historical ComparisonAbout SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
About GFUZ General Fusion Group Ltd. Common Shares
General Fusion Group Ltd is focused on developing fusion energy technology based on Magnetized Target Fusion (MTF), which combines magnetic confinement and mechanical compression to achieve fusion conditions. It operates a large-scale demonstration system, Lawson Machine 26 (LM26), intended to validate elements of its technology and support the development of commercial fusion power plants for electricity generation.